Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company focused on developing precision medicines for cancer treatment, is approaching a critical juncture in its development ...
The ultra-sensitive detection of MRD in AML is a critical tool for advancing clinical research in AML. NGS-based AML MRD is being more widely adopted in drug development and studies aiming to improve ...
The ultra-sensitive detection of MRD in AML is a critical tool for advancing clinical research in AML. NGS-based AML MRD is being more widely adopted in drug development and studies aiming to improve ...
Leukemic stem cells (LSCs) and stemness signatures contribute to minimal residual disease in patients with acute myeloid ...
Kura Oncology and Kyowa Kirin reported positive Phase 2 results for ziftomenib in AML and plan Phase 3 trials, with an NDA ...
Nana Kwame Wiredu Amoako is currently fighting for his life against Acute Myeloid Leukaemia (AML), a severe form of cancer.
Patients Achieved Remission Within 30 Days in Cohort 1 of the Mipletamig RAINIER Dose Optimization Trial for Frontline AML Patients, Trial Enrollment Continues Promising Data, including a 59% Stable ...
PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced ...
Today, OGT announces the North American launch of its new next-generation sequencing (NGS) SureSeq ™ Myeloid MRD Panel, which provides a flexible NGS workflow for the detection of ultra-low ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback